The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04712812
Recruitment Status : Recruiting
First Posted : January 15, 2021
Last Update Posted : September 7, 2023
Sponsor:
Collaborator:
CureAP4 Foundation
Information provided by (Responsible Party):
Darius Ebrahimi-Fakhari, Boston Children's Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) is focused on gathering longitudinal clinical data as well as biological samples (skin and/or blood and/or saliva) from male or female patients who exhibited onset of HSP symptoms at 18 years old or younger with (1) a clinical diagnosis of hereditary spastic paraplegia and/or (2) the presence of variants in HSP related genes and/or be a relative of a person with such a diagnosis. Currently, the treatment for this disorder is generally symptomatic and available therapies improve quality of life, but are grossly inefficient in slowing the disease progression. Access to the registry information will be limited to the study staff who are responsible for recruitment and maintenance of the registry. We hope that recruitment into registry for studies will advance knowledge of the causes, clinical course, diagnosis and treatment of these conditions.

Condition or disease
Hereditary Spastic Paraplegia SPG47 SPG50 SPG51 SPG52 AP4-related Hereditary Spastic Paraplegia Early Onset Hereditary Spastic Paraplegia SPG4 SPG3A SPG15 SPG11

Detailed Description:

The hereditary spastic paraplegias (HSP) are a group of more than 80 neurodegenerative diseases that lead to progressive neurological decline. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability.

We aim to delineate the core clinical, imaging, and molecular features of pediatric onset hereditary spastic paraplegia. This registry and natural history study will facilitate an early diagnosis, enables counseling and anticipatory guidance of affected families and will help define clinically meaningful endpoints for future interventional trials. Samples will be collected for the purpose of molecular and cellular investigation that will help identify biomarkers and novel targets for therapy. The samples and clinical information will be housed in the Translational Neuroscience Center and a secure REDcap database, respectively; both located in Boston Children's Hospital (BCH), but will be available to investigators around the world after approval.

The objectives of this protocol are to (1) To systematically document the clinical presentation and natural history of early-onset forms of HSP and (2) To facilitate an early diagnosis, enable counseling and anticipatory guidance of affected families and help define clinically meaningful endpoints for future interventional traits.

Specifically, the aims are to:

  1. Create a registry to perform an initial cross sectional analysis of clinical, imaging and molecular data to establish the disease spectrum.
  2. Create a repository of biological samples and collection of longitudinal clinical data that helps establish the natural history of early onset HSP.
  3. Create a registry that allows for re- identification and re-contact of participants by appropriate investigators.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 4 Years
Official Title: Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP)
Actual Study Start Date : April 27, 2020
Estimated Primary Completion Date : April 26, 2024
Estimated Study Completion Date : April 26, 2025

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Proband with AP-4 Associated HSP
Male or female patients of all ages with (1) onset of hereditary spastic paraplegia symptoms before the age of 18 years and/or (2) the presence of variants in HSP related genes and/or a relative of a person with such a diagnosis.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Establishment of data repository [ Time Frame: Through study completion, an average of 1 year ]
    Create a registry to perform an initial cross sectional analysis of clinical, imaging and molecular data to establish the disease spectrum.

  2. Establishment of bio-repository [ Time Frame: Through study completion, an average of 1 year ]
    Create a repository of biological samples and collection of longitudinal clinical data that helps establish the natural history of early onset HSP.

  3. Registry for recontact [ Time Frame: Through study completion, an average of 1 year ]
    Create a registry that allows for re-identification and re-contact of participants by appropriate investigators.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Days and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Male or female patients of all ages with onset of hereditary spastic paraplegia symptoms before the age of 18 years and/or an HSP related gene mutation, and/or their family members of interest (if applicable).
Criteria

Inclusion Criteria:

  • Onset of hereditary spastic paraplegia symptoms before the age of 18 years
  • The presence of variants in HSP related genes and/or a relative of a person with such a diagnosis

Exclusion Criteria:

  • Not having such a diagnosis and/or not being related to such individual
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04712812


Contacts
Layout table for location contacts
Contact: Darius Ebrahimi-Fakhari, MD, PhD 617-355-6388 hsp.research@childrens.harvard.edu
Contact: Amy Tam, BS 617-355-2698 hsp.research@childrens.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Darius Ebrahimi-Fakhari, MD, PhD    617-355-6388    Darius.Ebrahimi-Fakhari@childrens.harvard.edu   
Contact: Amy Tam, BS    16173552698    amy.tam@childrens.harvard.edu   
Principal Investigator: Darius Ebrahimi-Fakhari, MD, PhD         
Sponsors and Collaborators
Boston Children's Hospital
CureAP4 Foundation
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Darius Ebrahimi-Fakhari, Director, Movement Disorders Program, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT04712812    
Other Study ID Numbers: P00033016
First Posted: January 15, 2021    Key Record Dates
Last Update Posted: September 7, 2023
Last Verified: September 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Darius Ebrahimi-Fakhari, Boston Children's Hospital:
AP4-HSP
AP4
SPG
AP-4
AP-4-HSP
 Spastic Paraplegia
Adapter Protein 4
HSP
Early onset
Early onset HSP
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Spasticity
Paraplegia
Spastic Paraplegia, Hereditary
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Paralysis
 Hereditary Sensory and Motor Neuropathy
Nervous System Malformations
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Polyneuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Congenital Abnormalities
Genetic Diseases, Inborn